<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.2" -->
<rss version="2.0" 
	xmlns:content="http://purl.org/rss/1.0/modules/content/">
<channel>
	<title>Comments on: The End of the Empagran Saga. The D.C. Circuit Rules for the Defendants in Empagran II.</title>
	<link>http://www.antitrustreview.com/archives/175</link>
	<description>News and commentary about antitrust, economics, technology, policy</description>
	<pubDate>Thu, 20 Nov 2008 12:31:58 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2</generator>

	<item>
		<title>By: Antitrust Review &#187; Exclusionary Conduct and the Extraterritorial Application of US Antitrust Law</title>
		<link>http://www.antitrustreview.com/archives/175#comment-718</link>
		<author>Antitrust Review &#187; Exclusionary Conduct and the Extraterritorial Application of US Antitrust Law</author>
		<pubDate>Mon, 20 Feb 2006 18:24:23 +0000</pubDate>
		<guid>http://www.antitrustreview.com/archives/175#comment-718</guid>
		<description>&lt;p&gt;[...] This is the Empagran (2004) situation, which is a combination of (3) and (2). As a result of A&#8217;s and B&#8217;s foreign price fixing, D, a foreign buyer, pays inflated prices. But D is not the only one harmed by the cartel. C, a domestic buyer, also pays inflated prices. In that situation, does D have standing to sue in the US for its (foreign) harm? The answer to this question is still subject to controversy, but a conservative answer is: &#8220;Yes, provided that harm to C (= domestic harm) is the proximate cause of D&#8217;s (foreign) harm.&#8221; (But not vice versa.) [...]&lt;/p&gt;
</description>
		<content:encoded><![CDATA[<p>[&#8230;] This is the Empagran (2004) situation, which is a combination of (3) and (2). As a result of A&#8217;s and B&#8217;s foreign price fixing, D, a foreign buyer, pays inflated prices. But D is not the only one harmed by the cartel. C, a domestic buyer, also pays inflated prices. In that situation, does D have standing to sue in the US for its (foreign) harm? The answer to this question is still subject to controversy, but a conservative answer is: &#8220;Yes, provided that harm to C (= domestic harm) is the proximate cause of D&#8217;s (foreign) harm.&#8221; (But not vice versa.) [&#8230;]</p>]]></content:encoded>
	</item>
	<item>
		<title>By: Antitrust Review &#187; Extraterritorial Application of US Antitrust Law (Cheat Sheet)</title>
		<link>http://www.antitrustreview.com/archives/175#comment-686</link>
		<author>Antitrust Review &#187; Extraterritorial Application of US Antitrust Law (Cheat Sheet)</author>
		<pubDate>Sat, 04 Feb 2006 18:19:04 +0000</pubDate>
		<guid>http://www.antitrustreview.com/archives/175#comment-686</guid>
		<description>&lt;p&gt;[...] This is the Empagran (2004) situation, which is a combination of (3) and (2). As a result of A&#8217;s and B&#8217;s foreign price fixing, D, a foreign buyer, pays inflated prices. But D is not the only one harmed by the cartel. C, a domestic buyer, also pays inflated prices. In that situation, does D have standing to sue in the US for its (foreign) harm? The answer to this question is still subject to controversy, but a conservative answer is: &#8220;Yes, provided that harm to C (= domestic harm) is the proximate cause of D&#8217;s (foreign) harm.&#8221; (But not vice versa.) [...]&lt;/p&gt;
</description>
		<content:encoded><![CDATA[<p>[&#8230;] This is the Empagran (2004) situation, which is a combination of (3) and (2). As a result of A&#8217;s and B&#8217;s foreign price fixing, D, a foreign buyer, pays inflated prices. But D is not the only one harmed by the cartel. C, a domestic buyer, also pays inflated prices. In that situation, does D have standing to sue in the US for its (foreign) harm? The answer to this question is still subject to controversy, but a conservative answer is: &#8220;Yes, provided that harm to C (= domestic harm) is the proximate cause of D&#8217;s (foreign) harm.&#8221; (But not vice versa.) [&#8230;]</p>]]></content:encoded>
	</item>
	<item>
		<title>By: Antitrust Review &#187; Empagran Roundup</title>
		<link>http://www.antitrustreview.com/archives/175#comment-672</link>
		<author>Antitrust Review &#187; Empagran Roundup</author>
		<pubDate>Sat, 21 Jan 2006 21:27:55 +0000</pubDate>
		<guid>http://www.antitrustreview.com/archives/175#comment-672</guid>
		<description>&lt;p&gt;[...] Discussion of the D.C. Circuits Empagran II decision. [...]&lt;/p&gt;
</description>
		<content:encoded><![CDATA[<p>[&#8230;] Discussion of the D.C. Circuits Empagran II decision. [&#8230;]</p>]]></content:encoded>
	</item>
	<item>
		<title>By: Anonymous</title>
		<link>http://www.antitrustreview.com/archives/175#comment-667</link>
		<author>Anonymous</author>
		<pubDate>Fri, 20 Jan 2006 21:03:00 +0000</pubDate>
		<guid>http://www.antitrustreview.com/archives/175#comment-667</guid>
		<description>&lt;p&gt;Could you please re-post the cheatsheet.  It does not appear to be available on your blog anymore.  It was quite helpful.  Thanks very much.&lt;/p&gt;
</description>
		<content:encoded><![CDATA[<p>Could you please re-post the cheatsheet.  It does not appear to be available on your blog anymore.  It was quite helpful.  Thanks very much.</p>]]></content:encoded>
	</item>
</channel>
</rss>
